With FDA Decision Date Approaching, Analyst Downgrades Sarepta On Balanced Risk And Reward

RBC Capital Markets has downgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) as it weighs recent investor feedback, company commentary, and public statements from senior FDA officials.The analyst reports

Benzinga13:40

Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout

Seeking Alpha12:35

What the Options Market Tells Us About Johnson & Johnson

Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson (NYSE:JNJ), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unv

Benzinga12:16

The diet medicine market is optimistic that sentiment is heating up, and the latest forecast is that the size will reach 150 billion US dollars

① Aikunwei wrote in a report this month that, driven by multiple factors, the global obesity drug market is expected to reach 131 billion US dollars by 2028; ② The BMO capital market also estimates that by 2033, annual sales of diet pills will reach 150 billion US dollars.

cls.cn11:29

Novartis Reports Phase 3 Results for IgA Nephropathy Treatment

Seeking AlphaMay 28 08:44

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash

BenzingaMay 28 07:56